Loading
During intensive chemotherapy, when white cells are very low, the bowel wall can become inflamed and infected. Fever with tummy pain, diarrhoea or bloating is an emergency: ring your treatment helpline at once. In hospital it is confirmed with an ultrasound or CT scan and treated with strong antibiotics through a drip, fluids, pain relief and resting the bowel, with surgeons asked to see you.
Neutropenic enterocolitis complicates intensive chemotherapy, above all for acute leukaemia; AGIHO cites a pooled incidence of 5.3% in hospitalised patients with haematological cancers, aplastic anaemia or high-dose chemotherapy, and mortality from under 20% to 82%. High-dose cytarabine with anthracyclines is the main risk factor. A 2025 cohort of 178 episodes found it in 13.8% of AML induction courses and 9.5% of autologous transplants (higher with 7+3 induction and BEAM conditioning) with lower 30-day mortality than earlier reports.
AGIHO 2017: proposed diagnostic criteria are fever, abdominal pain and bowel wall thickening over 4 mm across more than 30 mm on ultrasound or CT; a clinical definition (temperature 37.8 °C or more with abdominal pain and/or no bowel movement for 72 hours or more) identifies neutropenic patients at risk earlier. Imaging confirms it and excludes perforation; blood and stool cultures and a C. difficile toxin test are recommended; endoscopy is discouraged because of perforation risk. Conservative therapy (bland diet, hydration, pain control; BIII); piperacillin-tazobactam, imipenem-cilastatin or meropenem (BIII), continued until clinical signs and neutropenia resolve; no evidence on adding metronidazole or vancomycin (CIII); empirical antifungal therapy may be discussed (BIII); growth factors might be considered (BIII). Surgical consultation early; surgery reserved for severe cases such as perforation (BIII).
Why: The formal definition describes late disease; this earlier clinical picture already predicts complications and death.
“Neutropenic patients with chemotherapy-associated bowel syndrome (T ≥ 37.8 °C and abdominal pain and/or lack of bowel movement for ≥ 72 h) were more likely to suffer complications and death [27].”
Why: Imaging shows the thickened bowel and whether it has burst, which changes treatment.
“Non-invasive imaging is generally recommended to confirm the diagnosis of NEC and to exclude bowel wall perforation.”
Why: Bacteria often enter the blood from the damaged bowel, and C. difficile colitis looks similar but is treated differently.
“Blood cultures, stool cultures, and a C. difficile toxin test for exclusion of NEC-associated bacteremia and colitis due to C. difficile, respectively, are recommended.”
Why: The inflamed bowel wall can tear.
“Endoscopy to obtain biopsies is discouraged, due to the increased risk of bowel wall perforation.”
Why: Most episodes settle as the blood count recovers, if the person is supported until then.
“Conservative therapy is preferred in most cases, consisting of a bland diet, hydration, and an effective pain treatment (BIII).”
Why: These broad antibiotics cover the gut bacteria, Gram-negative Enterobacteriaceae above all, most often found in the blood in this condition.
“Antimicrobial therapy should be administered until resolution of clinical signs and neutropenia.”
Why: Fungal infection is found in a minority of cases and is easily missed.
“Empirical antifungal therapy may be discussed if it has not yet been administered for the indication of persistent febrile neutropenia [68, 83, 84] (BIII).”
Why: Surgery while the blood count is low is risky, so it is reserved for when the bowel has burst or is failing.
“While a surgical consultation should be obtained at an early stage of disease evolution, surgical interventions in the neutropenic and/or thrombocytopenic patient are reserved to severe cases, e.g., patients with bowel wall perforation (BIII).”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The AGIHO/DGHO 2017 update is the only guideline read that addresses neutropenic enterocolitis directly; every recommendation it makes is grade B or C on level III evidence (expert opinion), because there are no trials. Its approach: early recognition, imaging to confirm and exclude perforation, cultures and a C. difficile test, no endoscopy, conservative care, piperacillin-tazobactam or a carbapenem until the neutropenia recovers, antifungal therapy considered, and early surgical review with surgery kept for perforation. Newer cohort data (Clinical Infectious Diseases 2025) refine who is at risk (7+3 AML induction, high-dose steroids, high blast counts, azacitidine, BEAM conditioning) but do not change management.
AGIHO/DGHO, Annals of Hematology 2017 · Clinical Infectious Diseases 2025
Where it differs: Adds metronidazole for extra anaerobic cover, or vancomycin, to piperacillin-tazobactam or a carbapenem.
Evidence: AGIHO found no studies of their effect on outcome and grades the question CIII.
Where it differs: Gives G-CSF to speed recovery of the neutrophil count.
Evidence: AGIHO: might be considered, though corresponding evidence is not available (BIII).
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Conservative therapy: bland diet, hydration, pain control | BIII | AGIHO/DGHO, Annals of Hematology 2017 |
| Piperacillin-tazobactam, imipenem-cilastatin or meropenem “In accordance with IDSA guidelines for patients with complicated abdominal infections in non-neutropenic patients [81] and the guideline for antimicrobial therapy of unexplained fever in neutropenic patients of the AGIHO [82], we recommend administration of piperacillin/tazobactam or imipenem/cilastatin or meropenem (BIII).” | BIII | AGIHO/DGHO, Annals of Hematology 2017 |
| Additional metronidazole or vancomycin “There are no studies assessing the effect of additional metronidazole or vancomycin on patient outcome (CIII).” | CIII | AGIHO/DGHO, Annals of Hematology 2017 |
| Haematopoietic growth factors “The use of hematopoietic growth factors might be considered, even though corresponding evidence is not available (BIII).” | BIII | AGIHO/DGHO, Annals of Hematology 2017 |
| Surgery reserved for severe cases such as perforation | BIII | AGIHO/DGHO, Annals of Hematology 2017 |
Shares Suspected febrile neutropenia (neutropenic sepsis): the first hour, Febrile neutropenia, Neutropenia, Acute lymphoblastic leukaemia and the tags protocol, neutropenic-sepsis.
Shares Suspected febrile neutropenia (neutropenic sepsis): the first hour, Filgrastim (G-CSF), Febrile neutropenia, Neutropenia and the tag protocol.
Shares Cytarabine, Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tags protocol, acute-oncology, oncological-emergency.
Shares Suspected febrile neutropenia (neutropenic sepsis): the first hour, Febrile neutropenia and the tags protocol, acute-oncology, oncological-emergency.
Shares Suspected febrile neutropenia (neutropenic sepsis): the first hour, Febrile neutropenia, Neutropenia, Acute lymphoblastic leukaemia and the tag protocol.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.